Navellier & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.19M | Buy |
28,575
+270
| +1% | +$58.1K | 0.57% | 36 |
|
|
2026
Q1 | $6.16M | Sell |
28,305
-1,261
| -4% | -$280K | 0.64% | 35 |
|
|
2025
Q4 | $6.76M | Sell |
29,566
-1,644
| -5% | -$375K | 0.76% | 30 |
|
|
2025
Q3 | $7.23M | Buy |
31,210
+278
| +0.9% | +$56.6K | 0.73% | 31 |
|
|
2025
Q2 | $5.74M | Sell |
30,932
-28
| -0.1% | -$5.2K | 0.71% | 34 |
|
|
2025
Q1 | $6.07M | Sell |
30,960
-2,473
| -7% | -$481K | 0.84% | 31 |
|
|
2024
Q4 | $5.94M | Sell |
33,433
-290
| -0.9% | -$53.3K | 0.71% | 34 |
|
|
2024
Q3 | $6.66M | Sell |
33,723
-1,362
| -4% | -$254K | 0.9% | 22 |
|
|
2024
Q2 | $6.02M | Sell |
35,085
-408
| -1% | -$67.6K | 0.71% | 29 |
|
|
2024
Q1 | $6.46M | Sell |
35,493
-1,571
| -4% | -$271K | 0.8% | 28 |
|
|
2023
Q4 | $5.74M | Buy |
37,064
+338
| +0.9% | +$49.3K | 0.86% | 27 |
|
|
2023
Q3 | $5.47M | Buy |
36,726
+7,399
| +25% | +$1.09M | 0.94% | 19 |
|
|
2023
Q2 | $3.95M | Sell |
29,327
-275
| -0.9% | -$40.3K | 0.77% | 42 |
|
|
2023
Q1 | $4.72M | Sell |
29,602
-192
| -0.6% | -$29.4K | 0.99% | 21 |
|
|
2022
Q4 | $4.81M | Buy |
29,794
+2,274
| +8% | +$349K | 0.98% | 25 |
|
|
2022
Q3 | $3.69M | Sell |
27,520
-222
| -0.8% | -$31.9K | 0.82% | 34 |
|
|
2022
Q2 | $4.25M | Buy |
27,742
+980
| +4% | +$150K | 0.91% | 34 |
|
|
2022
Q1 | $4.34M | Buy |
26,762
+1,510
| +6% | +$219K | 0.74% | 45 |
|
|
2021
Q4 | $3.42M | Sell |
25,252
-337
| -1% | -$39.8K | 0.5% | 66 |
|
|
2021
Q3 | $2.76M | Sell |
25,589
-472
| -2% | -$53.9K | 0.42% | 74 |
|
|
2021
Q2 | $2.94M | Buy |
26,061
+1,328
| +5% | +$150K | 0.44% | 77 |
|
|
2021
Q1 | $2.68M | Buy |
24,733
+1
| +0% | +$107 | 0.48% | 69 |
|
|
2020
Q4 | $2.65M | Sell |
24,732
-1,001
| -4% | -$96.2K | 0.48% | 72 |
|
|
2020
Q3 | $2.25M | Sell |
25,733
-1,030
| -4% | -$97K | 0.49% | 72 |
|
|
2020
Q2 | $2.63M | Sell |
26,763
-47
| -0.2% | -$4.14K | 0.62% | 56 |
|
|
2020
Q1 | $2.04M | Sell |
26,810
-3,175
| -11% | -$270K | 0.48% | 54 |
|
|
2019
Q4 | $2.65M | Buy |
29,985
+448
| +2% | +$37.2K | 0.43% | 67 |
|
|
2019
Q3 | $2.24M | Buy |
29,537
+1,158
| +4% | +$79.4K | 0.37% | 72 |
|
|
2019
Q2 | $2.06M | Sell |
28,379
-144
| -0.5% | -$11.3K | 0.32% | 86 |
|
|
2019
Q1 | $2.3M | Sell |
28,523
-881
| -3% | -$72.1K | 0.36% | 78 |
|
|
2018
Q4 | $2.71M | Sell |
29,404
-437
| -1% | -$38.4K | 0.46% | 49 |
|
|
2018
Q3 | $2.82M | Buy |
29,841
+123
| +0.4% | +$11.7K | 0.37% | 80 |
|
|
2018
Q2 | $2.75M | Sell |
29,718
-333
| -1% | -$32.5K | 0.38% | 74 |
|
|
2018
Q1 | $2.84M | Buy |
30,051
+1,612
| +6% | +$177K | 0.43% | 65 |
|
|
2017
Q4 | $2.75M | Sell |
28,439
-5,113
| -15% | -$482K | 0.51% | 60 |
|
|
2017
Q3 | $2.98M | Sell |
33,552
-288
| -0.9% | -$21.9K | 0.58% | 52 |
|
|
2017
Q2 | $2.45M | Buy |
33,840
+1,085
| +3% | +$72.9K | 0.37% | 89 |
|
|
2017
Q1 | $2.13M | Buy |
32,755
+4,928
| +18% | +$310K | 0.31% | 100 |
|
|
2016
Q4 | $1.74M | Buy |
27,827
+5,082
| +22% | +$310K | 0.29% | 104 |
|
|
2016
Q3 | $1.44M | Buy |
22,745
+5,722
| +34% | +$370K | 0.21% | 106 |
|
|
2016
Q2 | $1.05M | Buy |
17,023
+7,507
| +79% | +$457K | 0.16% | 94 |
|
|
2016
Q1 | $544K | Buy |
+9,516
| New | +$530K | 0.07% | 123 |
|
Other funds holding ABBV
Navellier & Associates's ABBV Position: Q2 2026 in Review
Navellier & Associates increased its AbbVie (ABBV) stake by 0.95% in Q2 2026, buying an estimated $58.1K and bringing the position to 28,575 shares worth $7.19M. The position accounts for 0.57% of the portfolio, ranked #36.
Navellier & Associates first reported a position in ABBV in Q1 2016 and has held it in 42 quarters since. The position peaked at $7.23M in Q3 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Navellier & Associates held 28,575 shares of AbbVie worth $7.19M as of Q2 2026.
- Navellier & Associates bought 270 AbbVie shares in Q2 2026, an estimated $58.1K.
- AbbVie made up 0.57% of Navellier & Associates's portfolio in Q2 2026, its #36 holding.
- Navellier & Associates first reported a position in AbbVie in Q1 2016 and has held it in 42 quarters since.
- Navellier & Associates's AbbVie position peaked at $7.23M in Q3 2025.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.